Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The e-SELECT Registry a MULTICENTER POST-MARKET SURVEILLANCE "A multicenter prospective observational registry of the CYPHER SELECT Sirolimus- eluting Coronary Stent and of all future generation of commercially approved Cordis Sirolimus- eluting Stents."

Next Previous
X
Search
Trial Profile

The e-SELECT Registry a MULTICENTER POST-MARKET SURVEILLANCE "A multicenter prospective observational registry of the CYPHER SELECT Sirolimus- eluting Coronary Stent and of all future generation of commercially approved Cordis Sirolimus- eluting Stents."

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms E-SELECT
  • Sponsors Cordis Corporation

    • Most Recent Events

    • 25 Aug 2011 Official Title amended, Company added as trial sponsor as reported by Clinical Trials Registry - India.
    • 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India, CTRI2008-091-000170).
    • 17 Dec 2009 Planned number of patients changed from 30000 to 15000 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top